EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies

Roxane Dilcher iD, Stephan Wall, Mattes Groß, Sabrina Katzdobler, Olivia Wagemann, Carla Palleis, Endy Weidinger, Urban Fietzek, Alexander Bernhardt, Carolin Kurz, Christian Ferschmann, Maximilian Scheifele und 18 weitere

Alzheimer's & Dementia · 2024-10 · 20 (10) · 6896-6909

DOI: 10.1002/alz.14185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 12.09.2024. Verfasst von Roxane Dilcher und 29 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Alzheimer Disease, Positron-Emission Tomography, Biomarkers, tau Proteins. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Monash University, Lüneburg Heritage, Thiemann Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker‐based workflows to assess 4R‐tauopathy (4RT) patients are currently missing. We suggest a novel biomarker‐based algorithm to characterize AD and 4RTs. METHODS We cross‐sectionally assessed combinations of cerebrospinal fluid measures (CSF p‐tau 181 and t‐tau) and 18 F‐PI‐2620 tau‐positron emission tomography (PET) in patients with AD ( n = 64), clinically suspected 4RTs (progressive supranuclear palsy or corticobasal syndrome, n = 82) and healthy controls ( n = 19). RESULTS Elevated CSF p‐tau 181 and cortical 18 F‐PI‐2620 binding was characteristic for AD while normal CSF p‐tau 181 with elevated subcortical 18 F‐PI‐2620 binding was characteristic for 4RTs. 18 F‐PI‐2620‐assessed posterior cortical hypoperfusion could be used as an additional neuronal injury biomarker in AD. DISCUSSION The specific combination of CSF markers and 18 F‐PI‐2620 tau‐PET in disease‐specific regions facilitates the biomarker‐guided stratification of AD and 4RTs. This has implications for biomarker‐aided diagnostic workflows and the advancement in clinical trials. Highlights Novel biomarker‐based algorithm for differentiating AD and 4R‐tauopathies. A combination of CSF p‐tau 181 and 18 F‐PI‐2620 discriminates AD versus 4R tauopathies. Hypoperfusion serves as an additional neuronal injury biomarker in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePositron-Emission TomographyBiomarkerstau ProteinsHumansFemaleMaleAgedCross-Sectional StudiesMiddle AgedTauopathies

Stichwörter der Autor:innen

18F‐PI‐26204‐repeat tauopathiesAlzheimer's diseasePETbiomarkerscerebrospinal fluidperfusiontau

Substanzen

Biomarkerstau Proteins

Autor:innen und Institutionen

  • Neuroscience, Monash University, Melbourne, Australia.
  • Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, München, Germany.
  • Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, München, Germany.
  • (SyNergy), Munich Cluster for Systems Neurology, München, Germany.
  • Department of Neurology, University Hospital of Munich, LMU Munich, München, Germany.
  • (DZNE), German Center for Neurodegenerative Diseases, München, Germany.

ORCID-Profile: Roxane Dilcher, Nicolai Franzmeier

Förderung

  • Monash University
  • Lüneburg Heritage
  • Thiemann Foundation
  • Deutsche Forschungsgemeinschaft (DFG)
  • German Federal Ministry of Education and Research

Zitieren

APA

Dilcher, R., Wall, S., Groß, M., Katzdobler, S., Wagemann, O., Palleis, C., Weidinger, E., Fietzek, U., Bernhardt, A., Kurz, C., Ferschmann, C., Scheifele, M., Zaganjori, M., Gnörich, J., Bürger, K., Janowitz, D., Rauchmann, B. S., Stöcklein, S., Bartenstein, P., …, & Brendel, M. (2024). Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies. Alzheimer's & Dementia, 20(10), 6896-6909. https://doi.org/10.1002/alz.14185

Vancouver

Dilcher R, Wall S, Groß M, Katzdobler S, Wagemann O, Palleis C, et al. Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies. Alzheimer's & Dementia. 2024;20(10):6896-6909. doi:10.1002/alz.14185

BibTeX
@article{Dilcher2024,
  author = {Dilcher, Roxane and Wall, Stephan and Groß, Mattes and Katzdobler, Sabrina and Wagemann, Olivia and Palleis, Carla and Weidinger, Endy and Fietzek, Urban and Bernhardt, Alexander and Kurz, Carolin and Ferschmann, Christian and Scheifele, Maximilian and Zaganjori, Mirlind and Gnörich, Johannes and Bürger, Katharina and Janowitz, Daniel and Rauchmann, Boris-Stephan and Stöcklein, Sophia and Bartenstein, Peter and Villemagne, Victor and Seibyl, John and Sabri, Osama and Barthel, Henryk and Perneczky, Robert and Schöberl, Florian and Zwergal, Andreas and Höglinger, Günter U and Levin, Johannes and Franzmeier, Nicolai and Brendel, Matthias},
  title = {Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {10},
  pages = {6896--6909},
  doi = {10.1002/alz.14185}
}
Kostenlos starten →